Munich – Private equity investors Future Capital AG Hessen Life Sciences Chemie, Strategic European Technologies N.V. and HeidelbergCapital Private Equity Fund I GmbH & Co. KG and the company’s management have sold enzyme supplier IEP GmbH to US-based Cambrex Corporation.
A team from CMS Hasche Sigle led by lead partner Stefan-Ulrich Müller advised the three private equity investors and IEP management on all aspects of the transaction.
Prior to the sale, IEP GmbH was 100% owned by the three investor companies and management. Headquartered in Wiesbaden, the company is a leading global provider of innovative bio-catalytic processes and enzymes. IEP possesses outstanding interdisciplinary expertise in biochemistry, molecular biology and chemistry as well as a portfolio of more than 100 enzymes under patent protection. Using enzyme-based procedures, IEP optimises the manufacturing processes of low molecular weight active pharmaceutical ingredients.
New York Stock Exchange-listed Cambrex Corporation is a leading manufacturer of pharmaceutical substances and supplier of active ingredients and services to the life sciences industry. The company has research and production facilities in the US and Europe.
Advisers CMS Hasche Sigle:
Stefan-Ulrich Müller, Corporate (Lead Partner)
Jill Theuring, Corporate
Sebastian Wilhelm, Corporate
Roland Wutzke, Tax
Dr Martina Jentsch, Employment Law
Sylle Schreyer-Bestmann, IP
Sabine Korthaus, IP
Dr Stefan Segger, Insurance Law